Several other equities research analysts have also issued reports on AUTL. William Blair reissued a “buy” rating on shares of Autolus Therapeutics in a research report on Wednesday, April 3rd. HC Wainwright reissued a “buy” rating and issued a $41.00 price objective (down previously from $45.00) on shares of Autolus Therapeutics in a research report on Friday, May 17th. Finally, Zacks Investment Research raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $45.50.
NASDAQ:AUTL traded down $0.44 during trading hours on Thursday, reaching $14.98. 82,500 shares of the company were exchanged, compared to its average volume of 96,656. Autolus Therapeutics has a 52-week low of $12.70 and a 52-week high of $53.24. The company’s 50 day moving average is $15.64. The stock has a market cap of $617.45 million and a price-to-earnings ratio of -10.55. The company has a current ratio of 10.66, a quick ratio of 10.66 and a debt-to-equity ratio of 0.12.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Autolus Therapeutics by 4,011.3% during the 4th quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock worth $6,666,000 after purchasing an additional 198,036 shares during the period. Geode Capital Management LLC acquired a new stake in Autolus Therapeutics during the 4th quarter worth about $322,000. Barclays PLC acquired a new stake in Autolus Therapeutics during the 4th quarter worth about $113,000. CWM LLC acquired a new stake in Autolus Therapeutics during the 1st quarter worth about $1,105,000. Finally, Marshall Wace LLP grew its position in Autolus Therapeutics by 93.4% during the 1st quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock worth $7,330,000 after purchasing an additional 112,489 shares during the period. 43.38% of the stock is owned by institutional investors.
About Autolus Therapeutics
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.
Recommended Story: What member countries make up the G-20?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.